|
|
July 1, 2009 - FDA notified healthcare professionals and patients that it has required the manufacturers of the smoking cessation aids varenicline (Chantix) and bupropion (Zyban and generics) to add new Boxed Warnings and develop patient Medication Guides highlighting the risk of serious neuropsychiatric symptoms in patients using these products. These symptoms include changes in behavior, hostility, agitation, depressed mood, suicidal thoughts and behavior, and attempted suicide. The added warnings are based on the continued review of postmarketing adverse event reports for varenicline and bupropion received by the FDA. These reports included those with a temporal relationship between the use of varenicline... [read full story]
With cold and flu season upon us, it's more important than ever to employ good practices to control the spread of infections and avoid illness. "We need to be proactive not only to keep ourselves healthy, but to avoid...
Author Summary The development of tissues and organs in the human body requires carefully regulated production of proteins by cells. Proteins permit the growth and development of the many varied structures required for a...
Health officials blame H1N1 for rise in flu complications leading to pneumonia High-risk adults urged to get H1N1, pneumonia vaccinations CDC: 7 million more doses of H1N1 vaccine now available, bringing total to 61.2 million...
